Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer

Lei He, Shouzhen Wu, Qiang Hao, Elhadji M. Dioum, Kuo Zhang, Cun Zhang, Weina Li, Wei Zhang, Yingqi Zhang, Jiming Zhou, Zhijun Pang, Lijuan Zhao, Xiaowen Ma, Meng Li, Qiuyang Zhang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Functional significance of co-expressed erythropoietin (EPO) and its receptor (EPOR) in non-small cell lung cancer (NSCLC) had been under debate. In this study, co-overexpression of EPO/EPOR was confirmed to be positively associated with poor survival in NSCLC. The serum EPO in 14 of 35 enrolled NSCLC patients were found elevated significantly and decreased to normal level after tumor resection. With primary tumor cell culture and patient-derived tumor xenograft (PDX) mouse model, the EPO secretion from the tumors of these 14 patients was verified. Then, we proved the patient derived serum EPO was functionally active and had growth promotion effect in EPO/EPOR overexpressed but not in EPO/EPOR under-expressed NSCLC cells. We also illustrated EPO promoted NSCLC cell proliferation through an EPOR/Jak2/Stat5a/cyclinD1 pathway. In xenograft mouse model, we proved local application of EPO neutralizing antibody and short hairpin RNA (shRNA) against EPOR effectively inhibited the growth of EPO/EPOR overexpressed NSCLC cells and prolonged survivals of the mice. Finally, EPO/EPOR/ Jak2/Stat5a/cyclinD1 signaling was found to be a mediator of hypoxia induced growth in EPO/EPOR overexpressed NSCLC. Our results illustrated a subgroup of NSCLC adapt to hypoxia through self-sustainable EPO/EPOR signaling and suggest local blockage of EPO/EPOR as potential therapeutic method in this distinct NSCLC population.

Original languageEnglish (US)
Pages (from-to)82352-82365
Number of pages14
JournalOncotarget
Volume8
Issue number47
DOIs
StatePublished - 2017

Fingerprint

Erythropoietin
Non-Small Cell Lung Carcinoma
Neoplasms
Heterografts
Growth
Erythropoietin Receptors
Primary Cell Culture
Neutralizing Antibodies
Serum
Small Interfering RNA
Cell Survival
Cell Proliferation

Keywords

  • Cell cycle
  • Hypoxia
  • NSCLC
  • Proliferation
  • Serum EPO

ASJC Scopus subject areas

  • Oncology

Cite this

Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer. / He, Lei; Wu, Shouzhen; Hao, Qiang; Dioum, Elhadji M.; Zhang, Kuo; Zhang, Cun; Li, Weina; Zhang, Wei; Zhang, Yingqi; Zhou, Jiming; Pang, Zhijun; Zhao, Lijuan; Ma, Xiaowen; Li, Meng; Zhang, Qiuyang.

In: Oncotarget, Vol. 8, No. 47, 2017, p. 82352-82365.

Research output: Contribution to journalArticle

He, L, Wu, S, Hao, Q, Dioum, EM, Zhang, K, Zhang, C, Li, W, Zhang, W, Zhang, Y, Zhou, J, Pang, Z, Zhao, L, Ma, X, Li, M & Zhang, Q 2017, 'Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer', Oncotarget, vol. 8, no. 47, pp. 82352-82365. https://doi.org/10.18632/oncotarget.19354
He, Lei ; Wu, Shouzhen ; Hao, Qiang ; Dioum, Elhadji M. ; Zhang, Kuo ; Zhang, Cun ; Li, Weina ; Zhang, Wei ; Zhang, Yingqi ; Zhou, Jiming ; Pang, Zhijun ; Zhao, Lijuan ; Ma, Xiaowen ; Li, Meng ; Zhang, Qiuyang. / Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer. In: Oncotarget. 2017 ; Vol. 8, No. 47. pp. 82352-82365.
@article{7340e032576a4795bd1745d0519c91f8,
title = "Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer",
abstract = "Functional significance of co-expressed erythropoietin (EPO) and its receptor (EPOR) in non-small cell lung cancer (NSCLC) had been under debate. In this study, co-overexpression of EPO/EPOR was confirmed to be positively associated with poor survival in NSCLC. The serum EPO in 14 of 35 enrolled NSCLC patients were found elevated significantly and decreased to normal level after tumor resection. With primary tumor cell culture and patient-derived tumor xenograft (PDX) mouse model, the EPO secretion from the tumors of these 14 patients was verified. Then, we proved the patient derived serum EPO was functionally active and had growth promotion effect in EPO/EPOR overexpressed but not in EPO/EPOR under-expressed NSCLC cells. We also illustrated EPO promoted NSCLC cell proliferation through an EPOR/Jak2/Stat5a/cyclinD1 pathway. In xenograft mouse model, we proved local application of EPO neutralizing antibody and short hairpin RNA (shRNA) against EPOR effectively inhibited the growth of EPO/EPOR overexpressed NSCLC cells and prolonged survivals of the mice. Finally, EPO/EPOR/ Jak2/Stat5a/cyclinD1 signaling was found to be a mediator of hypoxia induced growth in EPO/EPOR overexpressed NSCLC. Our results illustrated a subgroup of NSCLC adapt to hypoxia through self-sustainable EPO/EPOR signaling and suggest local blockage of EPO/EPOR as potential therapeutic method in this distinct NSCLC population.",
keywords = "Cell cycle, Hypoxia, NSCLC, Proliferation, Serum EPO",
author = "Lei He and Shouzhen Wu and Qiang Hao and Dioum, {Elhadji M.} and Kuo Zhang and Cun Zhang and Weina Li and Wei Zhang and Yingqi Zhang and Jiming Zhou and Zhijun Pang and Lijuan Zhao and Xiaowen Ma and Meng Li and Qiuyang Zhang",
year = "2017",
doi = "10.18632/oncotarget.19354",
language = "English (US)",
volume = "8",
pages = "82352--82365",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "47",

}

TY - JOUR

T1 - Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer

AU - He, Lei

AU - Wu, Shouzhen

AU - Hao, Qiang

AU - Dioum, Elhadji M.

AU - Zhang, Kuo

AU - Zhang, Cun

AU - Li, Weina

AU - Zhang, Wei

AU - Zhang, Yingqi

AU - Zhou, Jiming

AU - Pang, Zhijun

AU - Zhao, Lijuan

AU - Ma, Xiaowen

AU - Li, Meng

AU - Zhang, Qiuyang

PY - 2017

Y1 - 2017

N2 - Functional significance of co-expressed erythropoietin (EPO) and its receptor (EPOR) in non-small cell lung cancer (NSCLC) had been under debate. In this study, co-overexpression of EPO/EPOR was confirmed to be positively associated with poor survival in NSCLC. The serum EPO in 14 of 35 enrolled NSCLC patients were found elevated significantly and decreased to normal level after tumor resection. With primary tumor cell culture and patient-derived tumor xenograft (PDX) mouse model, the EPO secretion from the tumors of these 14 patients was verified. Then, we proved the patient derived serum EPO was functionally active and had growth promotion effect in EPO/EPOR overexpressed but not in EPO/EPOR under-expressed NSCLC cells. We also illustrated EPO promoted NSCLC cell proliferation through an EPOR/Jak2/Stat5a/cyclinD1 pathway. In xenograft mouse model, we proved local application of EPO neutralizing antibody and short hairpin RNA (shRNA) against EPOR effectively inhibited the growth of EPO/EPOR overexpressed NSCLC cells and prolonged survivals of the mice. Finally, EPO/EPOR/ Jak2/Stat5a/cyclinD1 signaling was found to be a mediator of hypoxia induced growth in EPO/EPOR overexpressed NSCLC. Our results illustrated a subgroup of NSCLC adapt to hypoxia through self-sustainable EPO/EPOR signaling and suggest local blockage of EPO/EPOR as potential therapeutic method in this distinct NSCLC population.

AB - Functional significance of co-expressed erythropoietin (EPO) and its receptor (EPOR) in non-small cell lung cancer (NSCLC) had been under debate. In this study, co-overexpression of EPO/EPOR was confirmed to be positively associated with poor survival in NSCLC. The serum EPO in 14 of 35 enrolled NSCLC patients were found elevated significantly and decreased to normal level after tumor resection. With primary tumor cell culture and patient-derived tumor xenograft (PDX) mouse model, the EPO secretion from the tumors of these 14 patients was verified. Then, we proved the patient derived serum EPO was functionally active and had growth promotion effect in EPO/EPOR overexpressed but not in EPO/EPOR under-expressed NSCLC cells. We also illustrated EPO promoted NSCLC cell proliferation through an EPOR/Jak2/Stat5a/cyclinD1 pathway. In xenograft mouse model, we proved local application of EPO neutralizing antibody and short hairpin RNA (shRNA) against EPOR effectively inhibited the growth of EPO/EPOR overexpressed NSCLC cells and prolonged survivals of the mice. Finally, EPO/EPOR/ Jak2/Stat5a/cyclinD1 signaling was found to be a mediator of hypoxia induced growth in EPO/EPOR overexpressed NSCLC. Our results illustrated a subgroup of NSCLC adapt to hypoxia through self-sustainable EPO/EPOR signaling and suggest local blockage of EPO/EPOR as potential therapeutic method in this distinct NSCLC population.

KW - Cell cycle

KW - Hypoxia

KW - NSCLC

KW - Proliferation

KW - Serum EPO

UR - http://www.scopus.com/inward/record.url?scp=85030854554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030854554&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19354

DO - 10.18632/oncotarget.19354

M3 - Article

C2 - 29137269

AN - SCOPUS:85030854554

VL - 8

SP - 82352

EP - 82365

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 47

ER -